Merck & Co. Inc. (MRK)

58.83
0.19 0.32
NYSE : Health Technology
Prev Close 58.64
Open 58.80
Day Low/High 58.66 / 59.27
52 Wk Low/High 52.83 / 66.41
Volume 9.59M
Avg Volume 12.59M
Exchange NYSE
Shares Outstanding 2.69B
Market Cap 157.93B
EPS 0.90
P/E Ratio 67.72
Div & Yield 1.92 (3.21%)

Latest News

Asia Benchmarks Sag; U.S. Stock Futures Edge Higher

Asia Benchmarks Sag; U.S. Stock Futures Edge Higher

Asia markets traded mostly lower Tuesday, with Hong Kong's benchmark down almost 500 points.

Dow Jumps 212 Points as Wall Street Shrugs Off Syria and Turns to Earnings

Dow Jumps 212 Points as Wall Street Shrugs Off Syria and Turns to Earnings

Stocks rise Monday as concerns over prolonged military action in Syria fade and the focus for investors shifts to a heavy upcoming slate of U.S. corporate earnings.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

The Worst Stock Market Plunge in Your Lifetime Is Coming: Jim Rogers

The Worst Stock Market Plunge in Your Lifetime Is Coming: Jim Rogers

Legendary investor Jim Rogers thinks the market is headed straight for a major sell off. Here's why.

Jim's Daily Rundown

Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!

Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data

Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data

The drugmakers on April 16 released data from their respective studies at the Association for Cancer Research's annual meeting in Chicago.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Stocks Rise on Softer U.S. Approach in China Trade War

Stocks Rise on Softer U.S. Approach in China Trade War

Stocks rise Monday following tweets from Donald Trump that appeared to indicate the U.S. was softening its approach in its trade battle with China.

Stock Futures Are on a Mild Tear Monday After Brutal Friday Selloff

Stock Futures Are on a Mild Tear Monday After Brutal Friday Selloff

Markets around the globe last week were tumultuous after both China and the U.S. proposed tariffs on imported goods as investors weigh whether the countries will come to the table to negotiate an end to the spat.

Incyte And Merck Provide Update On Phase 3 Study Of Epacadostat In Combination With KEYTRUDA® (pembrolizumab) In Patients With Unresectable Or Metastatic Melanoma

Incyte And Merck Provide Update On Phase 3 Study Of Epacadostat In Combination With KEYTRUDA® (pembrolizumab) In Patients With Unresectable Or Metastatic Melanoma

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that an external Data Monitoring Committee (eDMC) review of the pivotal Phase 3 ECHO-301/KEYNOTE-252...

The European Medicines Agency Accepts Regulatory Submission For LYNPARZA® (olaparib) In BRCA-Mutated HER2-Negative Metastatic Breast Cancer

The European Medicines Agency Accepts Regulatory Submission For LYNPARZA® (olaparib) In BRCA-Mutated HER2-Negative Metastatic Breast Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the US and Canada, today announced that the European Medicines Agency has validated for review the Marketing Authorization Application (MAA) for LYNPARZA ®...

Merck To Hold First-Quarter 2018 Sales And Earnings Conference Call On May 1

Merck To Hold First-Quarter 2018 Sales And Earnings Conference Call On May 1

Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.

Trump's Amazon Assault Shows He Can't Leave Well Enough Alone

Trump's Amazon Assault Shows He Can't Leave Well Enough Alone

The basic features of a prosperous corporate environment are all around us, but it's become difficult to stick to that narrative amid all the diversions, including from the President.

Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick

Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #12 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #187 spot out of 500.

Http://www.merck.com

Http://www.merck.com

Eisai Co., Ltd.

Merck Announces Appointment Of Jennifer Zachary As General Counsel

Merck Announces Appointment Of Jennifer Zachary As General Counsel

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Jennifer Zachary as general counsel, effective April 16, 2018.

Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections

Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections

Watch for these upstart names to topple some big-caps going forward.

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Jim Cramer focuses on Merck, Eli Lilly, Abbott Labs, Phillips 66, Five Below, and Cintas in the Lightning Round.

Capitol to Capital: Cramer's 'Mad Money' Recap (Wednesday 3/14/18)

Capitol to Capital: Cramer's 'Mad Money' Recap (Wednesday 3/14/18)

Do we trade on the news out of Washington? Jim Cramer talks about Larry Kudlow and his stand on economic growth.

First-Line Lung Cancer Data And Other New Research From Merck's Broad Oncology Program To Be Presented At AACR Annual Meeting

First-Line Lung Cancer Data And Other New Research From Merck's Broad Oncology Program To Be Presented At AACR Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research from Merck's broad oncology clinical program - across several major tumor types, as monotherapy and in combination -...

FDA Grants Priority Review To Merck's Supplemental Biologics License Application (sBLA) For KEYTRUDA® (pembrolizumab) For Treatment Of Advanced Cervical Cancer

FDA Grants Priority Review To Merck's Supplemental Biologics License Application (sBLA) For KEYTRUDA® (pembrolizumab) For Treatment Of Advanced Cervical Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

Buyers of Merck's Stock Have Become More Bullish in the Past 4 Months

Buyers of Merck's Stock Have Become More Bullish in the Past 4 Months

Let's review the charts and indicators to see where this move may carry in the weeks ahead.

Http://www.merck.com

Http://www.merck.com

Eisai Co., Ltd.

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.

Merck To Present New Data From Studies Of Investigational HIV Therapies Doravirine And MK-8591 At CROI 2018

Merck To Present New Data From Studies Of Investigational HIV Therapies Doravirine And MK-8591 At CROI 2018

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data from studies of Merck's robust HIV pipeline, including doravirine, a late-stage investigational non-nucleoside reverse...

TheStreet Quant Rating: C (Hold)